OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
October 02, 2017
The acquisition broadens the CDMO’s preclinical and clinical offering to include bioanalytical and drug discovery services.
September 26, 2017
Additional reactor capacity and a wastewater processing plant increase API manufacturing capacity at the Cambrex site in Kalskoga, Sweden.
ADC Bio announces plans to expand into clinical and commercial drug manufacturing for ADCs.
September 21, 2017
Ajinomoto Althea opens manufacturing suites in new high potency and antibody drug conjugate commercial facility.
September 19, 2017
The acquisition adds to Catalent’s capabilities in biologics development, analytical services, manufacturing, and finished product supply.
September 06, 2017
Matching the production requirements of a bio/pharma company with the manufacturing capabilities of a CMO is a delicate balance, requiring attitude shifts on both sides of the table.
September 02, 2017
Forced degradation studies can identify stability problems for drug substance and drug products.
Innovation speeds discovery, drives down costs, and improves productivity.
September 01, 2017
Regulatory outsourcing can result in improved compliance, greater transparency, higher productivity, increased cost-effectiveness, and desired strategic outcomes.
August 22, 2017
CDMO Micro-Sphere is investing CHF 21 million (approximately $21.63 million) into the expansion of its GMP manufacturing capabilities at its Swiss facility.